



INDEPENDENT AUDITOR'S REPORT

To
The Members of Shilpa Lifesciences Private Limited

Report on the Audit of the financial statements

Opinion

We have audited the financial statements of Shilpa Lifesciences Private Limited ("the Company"), which comprise the balance sheet as at 31st March 2024, and the statement of Profit and Loss, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024 and its losses, total comprehensive losses, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

Information Other than the financial statements and Auditor's Report

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors Report but does not include the financial statements and our auditor's report thereon, and the remaining sections of the Company's Annual Report, which are expected to be made available to us after that date.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the other sections of Annual Report (other than those mentioned above), if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the applicable laws and regulations.

Management's Responsibility for the financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.



Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143 (11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

1. As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in paragraph 2(f) below on reporting under rule 11(g);
- c) The Balance Sheet, the Statement of Profit and Loss (Incl. Comprehensive Income), the Statement of Cash Flows and the Statement of changes in Equity dealt with by this Report are in agreement with the books of account;
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31stMarch2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31stMarch2024 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) Since the Company's turnover as per the last audited financial statements is less than Rs.50 Crores and its borrowing from banks or financial institutions or any Body Corporate at any time during the year is less than Rs.25 Crores, the Company is exempted from getting report of the auditor with respect to existence of internal financial controls with reference to financial statements of the company and its operating effectiveness of such controls vide notification dated 13thJune 2017.
- g) Matter to be included in the Auditors' Report under Section 197(16) is applicable only to a public limited Company and not to a private limited company. Hence, not commented.

2. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- a) The Company does not have any pending litigations which would impact its financial position.
- b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

- d) (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (ii) The management has represented, that, to the best of it’s knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- e) The company has not paid any dividend during the year.
- f) Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2024. The said software did not have the feature of recording audit trail (edit log) facility and therefore the said facility has not operated throughout the year.

For Bohara Bhandari Bung And Associates LLP

Chartered Accountants

(Firm’s Regn No.008127S/S200013)

Sd/-

CA.Pankaj Kumar Bohara

Partner

Membership No.215471

Place: Raichur

Date: 22.05.2024

UDIN: 24215471BKGE0X7347



Annexure-"A" To Independent Auditors' Report on the IND-AS financial statements of Shilpa Lifesciences Private Limited.

(Referred to in paragraph 1 of Report on Other Legal and Regulatory Requirements section of our report of even date.)

The Annexure referred to in our report to the members of Shilpa Lifesciences Private Limited ('the Company') for the year ended 31stMarch 2024. We report that:

- i. According to the information and explanation given to us, The Company does not possess fixed assets or intangible assets during the year. Accordingly, the provisions of clause 3(ii)(a), (b), (c), (d) & (e) of the Order are not applicable.
- ii. According to the information and explanation given to us, The Company does not have any inventory and no working capital limits has been availed in excess of five crore rupees (at any point of time during the year), in aggregate, from banks or financial institutions on the basis of security of current assets. Accordingly, the provisions of clause 3(ii) (a) & (b) of the Order are not applicable.
- iii. According to the information and explanation given to us, the Company has not made any investments in, nor provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year. Accordingly, clause 3(iii) of the Order is not applicable.
- iv. According to the information and explanation given to us, the Company has not granted any loans, nor made any investment, nor has provided any guarantees or securities to parties covered section 185 and 186 of the Act. Accordingly, clause (iv) of the Order is not applicable.
- v. According to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of section 73 and 76 or any other relevant provisions of the Act and the rules framed there under. Accordingly, clause (v) of the order is not applicable to the company.
- vi. According to the information and explanations given to us, maintenance of cost accounting records is not applicable to the Company.
- vii. In respect of Statutory dues
 - a) The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Goods and Services Tax, income-tax, cess and any other statutory dues applicable to it, to the appropriate authorities. There are no other statutory dues as on the last day of the financial year concerned which are outstanding for a period of more than six months from the date, they became payable.
 - b) According to the information and explanations given to us by the management there are no dues of income-tax, Goods and Service Tax, customs duty and cess which have not been deposited on account of any dispute.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

- viii. According to the information and explanations give to us by the management there are no unrecorded transactions during the year in the books of accounts which are surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961. Accordingly, clause 3(vii) of the order is not applicable to the company.
- ix. a) According to the information and explanations given to us by the management, the Company has not defaulted in repayment of loans or borrowings or payment of interest thereon to any lender during the year. Accordingly, paragraph 3(ix) of the Order is not applicable.
- b) According to the information and explanation given to us the company has not been declared wilful defaulter by any bank or financial institution or other lender;
- c) According to the information and explanation given to us the company the Term loans were applied for the purpose for which they were obtained;
- d) According to the information and explanation given to us and on an overall examination of the financial statements of the company, the company has not raised on short term funds. Hence, reporting under Clause 3(ix)(d) is not applicable to the company;
- e) According to the information and explanation given to us the company, since the company does not have any subsidiary, associates or joint venture reporting under in clause no.3(ix)(e) of the order is not applicable to the Company;
- f) According to the information and explanation given to us the company, since the company does not have any subsidiary, associates or joint venture reporting under in clause no.3(ix)(f) of the order is not applicable to the Company.
- x. a) Based on the information and explanations given to us by the management, the Company has not raised any money by way of public offer. The Company has not raised any term loans during the year.
- b) Based on the information and explanations given to us by the management, the Company has neither made any preferential allotment nor any private placement of shares or convertible debentures during the year.
- Accordingly, paragraph 3(x) of the order is not applicable.
- xi. Based upon the audit procedures performed for the purpose of reporting the true and fair view of the IND-AS financial statements and as per the information and explanations given by the management, we report that no material fraud by the Company or on the Company, has been noticed or reported during the year.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the Order is not applicable.



BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the IND-AS financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanations given to us by the company it is not mandatory to have internal audit system in terms of sec.138 of the Companies Act,2013. Accordingly, paragraph 3(xiv) of the order is not applicable.
- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable.
- xvi. In our opinion and according to the information and explanation provided to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, paragraph 3(xvi) of the Order is not applicable.
- xvii. According to the information and explanation given to us and based on our examination of the records, the company has incurred cash losses of Rs. 0.21 Lakhs in the current financial year & Rs. 0.23 Lakhs in the immediately preceding financial year.
- xviii. As there has been no resignation of the statutory auditors during the year reporting under paragraph 3(xviii) of the order is not applicable.
- xix. According to the information and explanation given to us and based on our examination of the records, and on the basis of the financial ratios there exists no material uncertainty on the company's ability to meet its liabilities existing falling due within a period of one year from the balance sheet date.
- xx. According to the information and explanation given to us and further based on the examination of the records, provision of sec.135 of the Act pertaining to CSR are not applicable to the Company. Accordingly, paragraph 3(xx) of the order is not applicable.

For Bohara Bhandari Bung and Associates LLP
Chartered Accountants
(Firm Registration Number: 008127S/S200013)

Sd/-

CA Pankaj Kumar Bohara
Partner
Membership Number: 215471

Place: Raichur
Date: 22.05.2024

UDIN: 24215471BKGE0X7347

Shilpa Lifesciences Private Limited

Part - I - Balance Sheet as at 31 March, 2024

(All amounts are in Indian Rupees unless otherwise stated)

Particulars	Note	As At	As at
		31.03.2024	31.03.2023
		Audited	Audited
ASSETS			
Non-Current Assets			
a) Capital work- in- progress	2	22,029,619	2,535,747
b) Other non-current assets	3	24,484,596	24,484,596
Total Non-Current Assets		46,514,215	27,020,343
Current Assets			
a) Financial Assets :			
i) Cash and Cash equivalents	4	35,006	244,681
Total Current Assets		35,006	244,681
TOTAL ASSETS		46,549,222	27,265,024
EQUITY AND LIABILITIES			
Equity:			
a) Equity Share Capital	5	100,000	100,000
b) Other Equity	6	(59,412)	(38,264)
Total Equity		40,588	61,736
Liabilities:			
Non Current Liabilities			
a) Financial Liabilities :			
i) Borrowings	7	27,004,762	25,308,028
ii) Others	8	19,290,360	1,696,734
Total Non-Current Liabilities		46,295,122	27,004,762
Current Liabilities			
a) Other Current Liability	9	203,512	188,526
b) Provisions	10	10,000	10,000
Total Current Liabilities		213,512	198,526
TOTAL EQUITY & LIABILITIES		46,549,222	27,265,024

The accompanying notes form an integral part of the financial statements

As per our report of even date attached
for **Bohara Bhandari Bung And Associates LLP**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

for and on behalf of Board of Directors of
Shilpa Lifesciences Private Limited

Sd/-

Sd/-

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Vishnukanth Bhutada
DIN No.01243391
Director

Ramakant Innani
DIN No.03222748
Director

Place : Raichur
Date : 22/05/2024

Place : Raichur
Date : 22/05/2024

Shilpa Lifesciences Private Limited

Part - II - Statement of Profit and Loss for the year ended 31 March, 2024

(All amounts in Indian Rupees except share data and per share data unless otherwise stated)

Particulars	Note	For the Year ended 31.03.2024	For the Year ended 31.03.2023
		Audited	Audited
Income			
Revenue from Operations		-	-
Other Income		-	-
Total Income		-	-
Expenses			
Other Expenses	11	21,148	23,149
Total Expenses		21,148	23,149
Profit / (Loss) before exceptional items and tax		(21,148)	(23,149)
Exceptional (Income)/Expense		-	-
Profit / (Loss) before tax after exceptional Item		(21,148)	(23,149)
Tax expense			
1. Current Income tax		-	-
2. Deferred tax (Net)		-	-
Profit/(Loss) for the year		(21,148)	(23,149)
Other Comprehensive Income/(Loss)		-	-
Total Comprehensive Income/(Loss)		(21,148)	(23,149)
Earning per equity share for Rs.10/- face value	13		
Basic		(2.11)	(2.31)
Diluted		(2.11)	(2.31)
Weighted Average number of equity shares (Continuing Operations)			
Basic		10,000	10,000
Diluted		10,000	10,000

The accompanying notes form an integral part of the financial statements

As per our report of even date attached
for **Bohara Bhandari Bung And Associates LLP**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

for and on behalf of Board of Directors of
Shilpa Lifesciences Private Limited

Sd/-

Sd/-

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Vishnukanth Bhutada
DIN No.01243391
Director

Ramakant Innani
DIN No.03222748
Director

Place : Raichur
Date : 22/05/2024

Place : Raichur
Date : 22/05/2024

Shilpa Lifesciences Private Limited

Statement of Cash Flow for the year ended 31 March, 2024

(All amounts are in Indian Rupees unless otherwise stated)

Particulars	For the year ended 31.03.2024	For the year ended 31.03.2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit/(Loss) Before Tax (PBT)	(21,148)	(23,149)
Operating after working capital changes & Other Adjustments		
Adjustments for Increase / (Decrease) in Operating Liabilities		
- Other Current Liabilities	14,986	157,078
- Other Financial Liabilities	17,593,626	1,123,144
Net Cash flow generated from Operations	17,587,464	1,257,073
Less: Taxes Paid	-	-
Net Cash flow from Operating activities	17,587,464	1,257,073
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment		-
-Capital Work in Progress	(19,493,872)	(1,985,259)
Net cash used in Investing Activities	(19,493,872)	(1,985,259)
CASH FLOWS FROM FINANCING ACTIVITIES		
Loans and Borrowings	1,696,734	783,028
Net cash earned from Financing Activities	1,696,734	783,028
Net Increase/(decrease)in Cash and Cash Equivalents	(209,676)	54,842
Cash & Cash Equivalents at the Beginning of the year	244,682	189,840
Cash & Cash Equivalents at the end of the year	35,006	244,682

Components of Cash and Cash Equivalents	For the year ended 31.03.2024	For the year ended 31.03.2023
Balances with banks - on current accounts	35,006	244,681
Total Cash and Cash Equivalents	35,006	244,682

Reconciliation between opening and closing balance sheet for liabilities arising from financing activities as at March 31,2024

Particulars	As at April 1, 2023	Cash Flows	Non cash movement	As at March 31, 2024
Non-current borrowings	25,308,028	1,696,734	-	27,004,762

Note:

- 1.Previous year figures have been reclassified wherever necessary.
2. Cash Flow statement has been prepared under Indirect method as per Ind AS-7 "Statement of Cash flows" as prescribed u/s.133 of the Companies Act, 2013.

The accompanying notes form an integral part of the financial statements

As per our report of even date attached for **Bohara Bhandari Bung And Associates LLP** Chartered Accountants (Firm's Regn No.008127S/S-200013)

for and on behalf of Board of Directors of **Shilpa Lifesciences Private Limited**

Sd/-

Sd/-

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Vishnukanth Bhutada **Ramakant Innani**
DIN No.01243391 DIN No.03222748
Director Director

Place : Raichur
Date : 22/05/2024

Place : Raichur
Date : 22/05/2024

Shilpa Lifesciences Private Limited

Statement of Changes in equity for the year ended 31 March, 2024

(All amounts in Indian Rupees except share data and per share data unless otherwise stated)

A. Equity Share Capital

Particulars	Amount
Balance as at 01 April, 2022	100,000
Changes in equity share capital during the year	-
Balance as at 31 March, 2023	100,000
Changes in equity share capital during the year	-
Balance as at 31 March, 2024	100,000

B. Other Equity

Particulars	Reserves and Surplus (Retained Earnings)	Total
Balance as at 01 April, 2022	(15,115)	(15,115)
Profit/(Loss) for the year	(23,149)	(23,149)
Other Comprehensive income, net of tax	-	-
Addition/Deletion during the year	-	-
Balance as at 31 March, 2023	(38,264)	(38,264)
Profit/(Loss) for the year	(21,148)	(21,148)
Other Comprehensive income, net of tax	-	-
Addition/Deletion during the year	-	-
Balance as at 31 March, 2024	(59,412)	(59,412)

Note:

Retained Earnings: This Reserve represents the cumulative profits of the Company. This Reserve can be utilised in accordance with the provisions of the Companies Act, 2013.

The accompanying notes form an integral part of the financial statements

As per our report of even date attached
for **Bohara Bhandari Bung And Associates LLP**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

for and on behalf of Board of Directors of
Shilpa Lifesciences Private Limited

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Place : Raichur
Date : 22/05/2024

Sd/-

Vishnukanth Bhutada
DIN No.01243391
Director

Place : Raichur
Date : 22/05/2024

Sd/-

Ramakant Innani
DIN No.03222748
Director

Shilpa Lifesciences Private Limited

(All amounts in Indian Rupees except share data and per share data unless otherwise stated)

5 Equity Share Capital

Particulars	As at	As at
	31.03.2024	31.03.2023
Authorised Equity shares 1,00,000 Shares of Rs. 10/- each par value (PY 1,00,000 Shares of Rs.10/- Each)	1,000,000	1,000,000
	1,000,000	1,000,000
Issued subscribed & fully paid up Equity shares 10,000, Rs. 10/- each par value	100,000	100,000
TOTAL	100,000	100,000

a) Reconciliation of the number of shares.

Particulars	As at 31.03.2024		As at 31.03.2023	
	No.s	Amount	No.s	Amount
Shares outstanding at the beginning of the year	10,000	100,000	10,000	100,000
Shares Issued during the year face Value of Rs.10/-	-	-	-	-
Shares outstanding at the end of the year	10,000	100,000	10,000	100,000

b) Shareholders holding more than 5% shares in the Company

Particulars	31.03.2024			31.03.2023		
	No.s	Amount	% of Holding	No.s	Amount	% of Holding
1) Shilpa Medicare Ltd*	9,999	99,990	99.99%	9,999	99,990	99.99%

*Note: The above figures include 1 share held by Ramakant Innani in the representative capacity on behalf of Shilpa Medicare Ltd.

c) Shares held by promoters at the end of the year

Promoter Name	31.03.2024			31.03.2023		
	No of Shares	%of total shares	% of Change during the year	No of Shares	%of total shares	% of Change during the year
1) Shilpa Medicare Ltd	9,999	100%	0%	9,999	100%	0%

Rights and Restrictions attached to Equity Shares

1 The Company has issued Equity shares having face value of Rs.10/- per share. Each Share Holder is eligible for one vote per share. In case dividend is proposed by the Company it will be subject to the approval of the Board of Directors. In the event of liquidation, the equity share holders are eligible to receive balance assets remaining after repayment to all the preferential share capital holders, in the in proportion to their equity holding.

As per our report of even date attached
for **Bohara Bhandari Bung And Associates LLP**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

for and on behalf of Board of Directors of
Shilpa Lifesciences Private Limited

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Place : Raichur
Date : 22/05/2024

Sd/-

Vishnukanth Bhutada
DIN No,01243391
Director

Place : Raichur
Date : 22/05/2024

Sd/-

Ramakant Innani
DIN No,03222748
Director

NOTES TO THE FINANCIAL STATEMENTS

CORPORATE INFORMATION

Shilpa Lifesciences Private Limited is a Private Limited Company incorporated on 20/07/2021, with its registered office at 12-6-214/A-1, Shilpa House Hyderabad Road, RAICHUR -584135 Karnataka. Presently, the Company is engaged in the business of Biotechnology using sophisticated technology meticulously in order to comply with laid down international standards/specifications. The company is a wholly owned subsidiary of Shilpa Pharma Lifesciences Limited. Further, the company is exploring various business opportunities as at the balance sheet date.

1. Basis of Preparation

a. Statement of Compliance

These financial statements have been prepared in accordance with the Indian Accounting Standards (Ind AS) as specified under section 133 of the Companies Act 2013 read together with the Rule 4 of Companies (Indian Accounting Standards) Rules, 2015 to the extent applicable and the other relevant provisions and presentation requirements of Division II of Schedule III to the Act, as applicable.

The financial statements of the Company for the year ended March 31, 2024 were approved by the Board of Directors on 22/05/2024.

The financial statements have been prepared to comply in all material aspects with applicable accounting principal in India and as notified under the Companies Act, 2013 and the other relevant provisions of the Act.

The Ind AS Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities as specified and defined benefit plans which have been measured at actuarial valuation as required by relevant Ind AS.

b. Functional and Presentation currency:

These financial statements are presented in Indian rupees ("INR") which is also the Company's functional currency. All amounts have been reported in Indian Rupees, except for share and per share data, unless otherwise stated. Due to rounding off, the numbers presented throughout the document may not add up precisely to the totals and percentages may not precisely reflect the absolute figures.

c. Basis of Measurement

The Standalone financial statements have been prepared on the historical cost basis (i.e. on accrual basis), except for the following assets and liabilities which have been measured at fair value wherever applicable

- Certain financial assets / liability measured at fair value,
- Net defined benefit assets/(liability) are measured at fair value of plan assets, less present value of defined benefit obligations.

d. Critical accounting Estimates and Judgements:

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Revisions to accounting estimates are recognised prospectively. The changes in the estimates are reflected in the Standalone financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the Standalone financial statements.

The areas involving critical estimates or judgments are:

- Estimation of Useful life of Property, plant and equipment and intangibles (Note 1.1 (a))
- Recognition of deferred taxes (Note 1.1(d))
- Provision for income taxes and related tax contingencies. (Note 1.1(d))
- Estimation of provision and contingent liabilities (Note 1.1(e))

1.1 Material Accounting policies

a. Property, Plant and Equipment & Depreciation:

- i. Items of property, plant and equipment are stated at cost less accumulated depreciation and impairment losses if any. Cost comprises of purchase price and any attributable cost of bringing the assets to its working condition for its intended use.
- ii. Capital work-in-progress in respect of assets which are not ready for their intended use are carried at cost, comprising of direct costs, related incidental expenses and attributable interest. Capital work-in-progress (CWIP) includes cost of property, plant and equipment under installation/under development as at the balance sheet date. Directly attributable expenditure (including finance costs relating to borrowed funds/general borrowings for construction or acquisition of property, plant and equipment) incurred on project under implementation are treated as pre-operative expenses pending allocation to the asset and are shown under CWIP.
- iii. Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.
- iv. Depreciation on Fixed Assets is provided on ascertain useful life of assets under Straight Line Method (SLM) prescribed in Schedule II of the Companies act-2013, with exception of those assets whose useful life is ascertain by the management.
- v. Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate. Based on technical evaluation and consequent advice, the management believes that its estimates of useful lives as given above best represent the period over which management expects to use these assets.
- vi. The Company follows the policy of charging depreciation on pro-rate basis on the assets acquired or disposed off during the year.
- vii. Advances paid towards the acquisition of property, plant and equipment outstanding at each balance sheet date is classified as capital advances under "Other Non-Current Assets."

b. Leases

Company as a lessee

The company recognises a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, company's incremental borrowing rate. Generally, the company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- Fixed payments, including in-substance fixed payments;
- Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- Amounts expected to be payable under a residual value guarantee; and
- The exercise price under a purchase option that the company is reasonably certain to exercise, lease payments in an optional renewal period if the company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the company is reasonably certain not to terminate early.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the company's estimate of the amount expected to be payable under a residual value guarantee, or if company changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero. The company presents right-of-use assets that do not meet the definition of investment property in 'property, plant and equipment' and lease liabilities in 'loans and borrowings' in the statement of financial position.

Short-term leases and leases of low-value assets

The company has elected not to recognise right-of-use assets and lease liabilities for short term leases of real estate properties that have a lease term of 12 months. The company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

c. Financial Instrument:

A financial instrument is any contract that gives rise to a financial asset of one entity and financial liability or equity instrument of another entity.

(I) Financial Asset:

Initial recognition and measurement

All financial instruments are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through P&L, transaction costs that are attributable to the acquisition of the financial asset, purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place are recognized on the trade date i.e. the date that the company commits to purchase or sell the asset.

Subsequent Measurement

For the purpose of subsequent measurement financial assets are classified as measured at:

- Amortised cost
- Fair value through profit and loss (FVTPL)
- Fair value through other comprehensive income (FVOCI).

(a) Financial Asset measured at amortized cost

Financial Assets held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding are measured at amortized cost using effective interest rate (EIR) method. The EIR amortization is recognized as finance income in the statement of Profit & Loss. The company while applying above criteria has classified the following at amortized cost:

- (a) Trade receivables
- (b) Loans
- (c) Other financial assets

(b) Financial Assets Measured at fair value through other comprehensive income

Financial assets that are held within a business model whose objective is achieved by both, selling financial assets and collecting contractual cash flows that are solely payments of principal and interest, are subsequently measured at fair value through other comprehensive income. Fair value movements are recognized in the other comprehensive income (OCI). Interest income measured using the EIR method and impairment losses, if any are recognized in the Statement of Profit and Loss. On derecognition, cumulative gain or loss previously recognised in OCI is reclassified from the equity to 'other income' in the Statement of Profit and Loss.

(c) Financial Assets at fair value through profit or loss (FVTPL)

Financial Asset are measured at Fair value through Profit & Loss if it does not meet the criteria for classification as measured at amortized cost or at FVTOCI. All fair value changes are recognized in the statement of Profit & Loss.

Equity Instruments

All investments in equity instruments classified under financial assets are initially measured at fair value, the group may, on initial recognition, irrevocably elect to measure the same either at FVOCI or FVTPL.

De-recognition of Financial Assets:

Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire or the financial asset is transferred and the transfer qualifies for Derecognition. On Derecognition of a financial asset in its entirety, the difference between the carrying amount (measured on the date of recognition) and the consideration received (including any new asset obtained less any new liability assumed) shall be recognized in the statement of Profit & Loss.

Impairment of Financial Assets:

In accordance with Ind AS 109, the company applies expected credit loss (ECL) model by adopting the simplified approach using a provision matrix reflecting current condition and forecasts of future economic conditions for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- (a) Financial Assets that are debt instruments, and are measured at amortized cost e.g. loans, debt securities, deposits, trade receivables and bank balance
- (b) Financial Assets that are debt instruments and are measured at FVTOCI.
- (c) Lease receivables under Ind AS 17.
- (d) Trade receivables or any contractual right to receive cash or another financial asset
- (e) Loan commitments which are not measured at FVTPL
- (f) Financial guarantee contracts which are not measured at FVTPL

(II) Financial Liability

Initial recognition and measurement

Financial liabilities are recognized initially at fair value plus any transaction cost that are attributable to the acquisition of the financial liability except financial liabilities at FVTPL that are measured at fair value.

Subsequent measurement

Financial liabilities are subsequently measured at amortised cost using the EIR method. Financial liabilities carried at fair value through profit or loss are measured at fair value with all changes in fair value recognised in the Statement of Profit and Loss.

Financial Liabilities at amortized cost:

Amortized cost for financial liabilities represents amount at which financial liability is measured at initial recognition minus the principal repayments, plus or minus the cumulative amortization using the effective interest method of any difference between the initial amount and the maturity amount.

The company is classifying the following under amortized cost

- Borrowings from banks
- Borrowings from others
- Other Financial Liabilities

Derecognition:

A financial liability shall be derecognized when, and only when, it is extinguished i.e. when the obligation specified in the contract is discharged or cancelled or expires.

d. Taxes on Income:

Income tax comprises of current and deferred income tax. Income tax expense is recognised in statement of profit and loss except to the extent that it relates to an item recognised directly in equity in which case it is recognised in other comprehensive income. Current income tax for current year and prior periods is recognised at the amount expected to be paid or recovered from the tax authorities, using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis.

Deferred tax is recognised in respect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Deferred income tax assets and liabilities are measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognised as income or expense in the period that includes the enactment or substantive enactment date. A deferred income tax assets is recognised to the extent it is probable that future taxable income will be available against which the deductible temporary timing differences and tax losses can be

utilised. The Company offsets income-tax assets and liabilities, where it has a legally enforceable right to set off the recognised amounts and where it intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

e. Provisions, Contingent Liabilities and Contingent Assets

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. If effect of the time value of money is material, provisions are discounted using an appropriate discount rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the Standalone financial statements

f. Borrowing Cost

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing cost eligible for capitalization.

Other borrowings costs are expensed in the period in which they are incurred.

g. Earnings per share

The Company presents basic and diluted earnings per share ("EPS") data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period.

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.

h. Cash Flow Statements

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

i. Cash and Cash Equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand, short-term deposits and other short-term highly liquid investments with an original maturity of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.

j. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the Consolidated balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

k. Recent accounting developments

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

2 Capital work-in-progress (Refer Note 15)

Particulars	As at 31.03.2024	As at 31.03.2023
Pre-Operative Expenses:		
Opening Balance	2,535,747	-
Additions during the year	19,493,872	2,535,747
Deductions during the year	-	-
Closing Balance	22,029,619	2,535,747

3 Other non-current assets

Particulars	As at 31.03.2024	As at 31.03.2023
Advance for Lease hold land (KIADB)	24,484,596	24,484,596
TOTAL	24,484,596	24,484,596

4 Cash and Cash Equivalents

Particulars	As at 31.03.2024	As at 31.03.2023
Balance with banks in current account	35,006	244,681
TOTAL	35,006	244,681

6 Other Equity

Particulars	As at 31.03.2024	As at 31.03.2023
<u>Retained Earnings</u>		
Opening Balance as on 01.04.2023	(38,264)	(15,115)
Add: Profit / (Loss) for the year	(21,148)	(23,149)
TOTAL	(59,412)	(38,264)

7 Financial Liabilities

Borrowings

Particulars	As at 31.03.2024	As at 31.03.2023
Unsecured Loan from	27,004,762	25,308,028
1) Shilpa Medicare Ltd (Holding Company)		
Terms of repayment		
The cumulative loan outstanding as on 5th Year is repayable over a period of 8 Years, from the date of first drawdown, including moratorium period of 5 Years in 12 equal quarterly installments starting from the 6th year. First installment falling due on 03.03.2027.		
Rate of Interest		
Interest is charged at 7.50%(PY 7.50%)p.a during the year		
TOTAL	27,004,762	25,308,028

Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

8 Financial Liabilities

Others-Refer Note No-18

Particulars	As at 31.03.2024	As at 31.03.2023
Interest accrued but not due on borrowings	1,831,606	1,696,734
Interest accrued & due - KIADB	17,458,754	-
TOTAL	19,290,360	1,696,734

9 Other Current Liabilities

Particulars	As at 31.03.2024	As at 31.03.2023
Tax deduction at source	203,512	188,526
TOTAL	203,512	188,526

10 Provisions

Particulars	As at 31.03.2024	As at 31.03.2023
Provision for Audit Fee	10,000	10,000
TOTAL	10,000	10,000

11 Other Expenses

Particulars	For the Year ended 31.03.2024	For the Year ended 31.03.2023
a) Bank Charges	648	649
b) Rates & Taxes	2,800	4,800
c) Payment to Auditors (Ref below note no:12)	15,000	15,000
d) GST input expensed	2,700	2,700
TOTAL	21,148	23,149

12 Payment to Statutory Auditors

Particulars	For the Year ended 31.03.2024	For the Year ended 31.03.2023
a) Statutory Audit	10,000	10,000
b) Income Tax Matters	5,000	5,000
TOTAL	15,000	15,000

13 Earning per share

Particulars	For the Year ended 31.03.2024	For the Year ended 31.03.2023
Earning per share		
Net profit/(loss) after taxes	(21,148)	(23,149)
Weighted Average No. of Equity shares	10,000	10,000
Face Value	10	10
Basic & Diluted	(2.11)	(2.31)

Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

14 Related Party Transactions

Related parties where control exists and related parties with whom transactions have taken place during the year are listed below

1 Holding Company

Shilpa Medicare Limited - Holding Company

SL No	Name of related Party	Relationship	Descriptions of Transaction	2023-24		2022-23	
				Income / (expense) / other transaction	Balance at 31.03.2024 Payable / (Receivable)	Income / (expense) / other transaction	Balance at 31.03.2023 Payable / (Receivable)
i	Shilpa Medicare Limited	Holding Company	Reimbursement of expenses	(188,526)	-	(131,448)	-
			<u>Unsecured Loan</u>				
			Opening balance	-	(25,308,028)	-	24,808,028
			Received during the year	250,000	-	500,000	-
			Repaid during the year	(250,000)	-	-	-
			Closing balance	-	27,004,762	-	(25,308,028)
			Maximum balance outstanding	-	27,254,762	-	(25,308,028)
			Interest on Loan	(2,035,118)	(1,831,606)	(1,885,260)	(1,696,734)

Note: The Above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures" and Companies Act, 2013.

Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

15 Capital-Work-in Progress (CWIP) -31.03.2024

Particulars	Amount in CWIP for a period of				As at 31 March, 2024
	Less than 1	1-2 years	2-3 Years	More than 3 years	
i) Projects in progress	19,493,872	2,535,747	-	-	22,029,619
ii) Projects temporarily suspended	-	-	-	-	-

Capital-Work-in Progress (CWIP) -31.03.2023

Particulars	Amount in CWIP for a period of				As at 31 March, 2023
	Less than 1	1-2 years	2-3 Years	More than 3 years	
i) Projects in progress	2,535,747	-	-	-	2,535,747
ii) Projects temporarily suspended	-	-	-	-	-

16 Financial Ratios

Particular	Numerator	Denominator	31st March 2024	31st March 2023	Variation %	Reasons for variance of above 25%
1. Current Ratio(in times)	Current Assets	Current Liabilities	0.16	1.23	-86.70%	Variance is primarily on account of decrease in bank balance during the year
2. Debt Equity Ratio(in times)	Total Debt	Share holder equity	665.34	409.94	62.30%	Variance is primarily on account of significant increase in the loan borrowed during the year.
3. Debt service coverage ratio(in times)	Earnings available for debt service	debt service	(0.16)	(0.02)	857.58%	Variance is primarily on account of significant increase in the interest payable on loan borrowed during the previous year.
4. Inventory turnover ratio(in times)	Sales	Inventory	-	-	NA	Since there is "NIL" Sales & Inventory
5. Return on equity(in %)	Net profit after taxes	Average shareholders equity	(0.10)	(0.08)	30.90%	Variance is primarily on account of loss during the during the year.
6. Trade receivable turnover ratio(in times)	Revenue	Trade Receivables	-	-	NA	Since there is "NIL" Turnover & Trade receivable
7. Trade payable turnover ratio(in times)	Purchase for trade and services	Average Trade Payables	-	-	NA	Since there is "NIL" Turnover & Trade Payable
8. Net Capital turnover ratio(in times)	Revenue	Working Capital	-	-	NA	Since there is "NIL" Revenue
9. Net Profit ratio(in %)	Net Profit	Revenue	-	-	NA	Since there is "NIL" revenue/income.
10. Return on Capital Employed(%)	Earning Before Interest and Tax	Capital Employed	-0.08%	-0.05%	70.98%	Variance is primarily on account of significant increase in the loan borrowed during the year.
11. Return on investment (in %)	Income generated from invested funds	Average invested funds in treasury investments	-	-	-	The Company has not made any investments during the period ended 31 March 2024 and 31 March 2023 respectively. Accordingly, the ratio pertaining to Return on investment has not been disclosed.

Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

17 Fair value measurement hierarchy

Particulars	FVTPL	FVTOCI	Amortised cost	Total
As at 31.03.2024				
Non-current Assets				
Investments	-	-	-	-
Loans	-	-	-	-
Current Financial Assets				
Cash & Bank Balance	-	-	35,006	35,006
Trade Receivable	-	-	-	-
Total			35,006	35,006
Non-Current Financial Liability				
Borrowings	-	-	27,004,762	27,004,762
Other financial liabilities	-	-	19,290,360	19,290,360
Current Financial Liability				
Trade payables	-	-	-	-
Total	-	-	46,295,122	46,295,122
As at 31.03.2023				
Non-current Assets				
Investments	-	-	-	-
Loans	-	-	-	-
Current Financial Assets				
Cash & Bank Balance	-	-	244,681	244,681
Trade Receivable	-	-	-	-
Total	-	-	244,681	244,681
Non-Current Financial Liability				
Borrowings	-	-	25,308,028	25,308,028
Other financial liabilities	-	-	1,696,734	1,696,734
Current Financial Liability				
Trade payables	-	-	-	-
Total	-	-	27,004,762	27,004,762

Fair value hierarchy

The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable and consist of the following three levels:

- Level 1 — Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 — Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 — Inputs are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

18 Financial Risk Management

The Company's activities expose it to a variety of financial risks such as Market Risk, Credit Risk and Liquidity Risk. The Company focuses on minimizing potential adverse effect on its financial performance.

(A) Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The changes in the values of financial assets / liability may result from change in the foreign currency exchange rates (Foreign Currency Risk), change in interest rates (Cash flow & interest rate risk), and change in price of investments (Price Risk). However, the company is not exposed to market risk

(i) Foreign Currency Risk

The Company does not operate internationally. Hence, the company is not exposed to foreign risk.

(ii) Interest Rate Risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The company does not have any floating rate borrowings and hence there is no interest rate risk.

(iii) Price Risk

Company does not have any exposure to price risk, as there is no market based equity instrument made by the Company.

(B) Credit Risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The credit risk arises from its operation activity primarily from trade receivable and from its financial activity. Customer credit risk is controlled by analysis of credit limit and credit worthiness of the customer on a continuous basis to whom the credit has been granted.

The company does not have trade receivables at the year end, hence the company is not exposed to credit risk.

(C) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations of its financial liability. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for making payment towards liability when they are due, under normal and stressed condition without incurring losses and risk.

The financial needs are taken care by the Holding Company and that there are no outside liabilities hence no liquidity risk is perceived.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March, 2024

Particulars	On Demand	< 01 Year	01 to 5 Years	> 05 Year
(i) Trade Payable	-	-	-	-
(ii) Other financial liabilities	-	19,290,360	-	-
(iii) Borrowings	-	-	27,004,762	-
Total	-	19,290,360	27,004,762	-

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March, 2023

Particulars	On Demand	< 01 Year	01 to 5 Years	> 05 Year
(i) Trade Payable	-	-	-	-
(ii) Other financial liabilities	-	1,696,734	-	-
(iii) Borrowings	-	-	25,308,028	-
Total	-	1,696,734	25,308,028	-

19 Capital Management

The Company's objectives when managing capital are to:

i) Safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders.

ii) Maintain an optimal capital structure to reduce the cost of capital.

Consistent with others in the industry, the Company monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings net of cash and cash equivalents) divided by total 'equity' (as shown in the balance sheet)

Particulars	31-Mar-24	31-Mar-23
Net Debt	27,004,762	25,308,028
Total Equity	40,588	61,736
Debt Equity Ratio	665.34	409.94

20 Additional Regulatory Information**20.01 Title deeds of immovable properties**

The Company is not holding any immovable property in its name hence reporting under this clause is not applicable.

20.02 Loans or advances to specified persons

No loans or advances in the nature of loans are granted to promoters, directors, KMPS and the related parties (as defined under Companies Act, 2013.) either severally or jointly with any other person, that are repayable on demand or without specifying any terms or period of repayment.

- 20.03 Details of benami property held**
No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- 20.04 Wilful defaulter**
The Company has not been declared wilful defaulter by any bank or financial institution or other lender.
- 20.05 Relationship with struck off companies**
The Company has no transactions with the companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956.
- 20.06 Registration of charges or satisfaction with Registrar of Companies (ROC)**
There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.
- 20.07 Compliance with approved scheme(s) of arrangements**
The Company has complied with the number of layers prescribed under the Section 2(87) of the Companies Act, 2013 read with Companies (Restriction on number of layers) Rules, 2017.
- 20.08 Undisclosed income**
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded previously in the books of account.
- 20.09 Details of crypto currency or virtual currency**
The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- 20.10 Utilisation of borrowings availed from banks and financial institutions**
There is no borrowings taken by the company from any banks or financial institutions during the current or previous year.
- 21 All Figures have been rounded off to the nearest rupees.
- 22 Figures of the previous year have been regrouped or rearranged wherever necessary.

The accompanying significant accounting policies and notes form an integral part of the financial statements.

As per our Report of even date attached
for **Bohara Bhandari Bung And Associates LLP**
Chartered Accountants
(Firm's Regn No.008127S/S-200013)

for and on behalf of the Board of Directors of
Shilpa Lifesciences Private Limited

Sd/-

Sd/-

Sd/-

CA. Pankaj Kumar Bohara
Partner
M.No.215471

Vishnukanth Bhutada
Director
DIN No.01243391

Ramakant Innani
Director
DIN No.03222748

Place : Raichur
Date : 22/05/2024

Place : Raichur
Date : 22/05/2024